Avidity Biosciences
Clinical-stage biotechnology company developing Antibody Oligonucleotide Conjugates (AOCs) for serious diseases.
About
Avidity Biosciences is developing a new class of targeted RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). These AOCs combine monoclonal antibodies and oligonucleotides to deliver therapies to previously inaccessible tissues and target the underlying genetic drivers of diseases. The company is currently advancing programs for rare muscle diseases including myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy.
Key facts
- Website
- aviditybiosciences.com
- Headquarters
- San Diego, United States
- Founded
- 2013
- Employees
- 445
- Total funding
- $495M (IPO)
- Valuation
- Private
- Business model
- B2B
- Tags
- BiotechDrug DiscoveryGenomicsClinical TrialsRare Diseases
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 9 Oct 2020 | IPO | $280M | - |
| 1 May 2020 | Series C | $100M | RTW Investments |
| 1 Mar 2019 | Series B | $100M | OrbiMed |
| 1 Mar 2018 | Series A | $15M | Takeda Ventures |
Tech stack
Detected on aviditybiosciences.com, last scanned 12 Aug 2026. Run your own scan
- Frontend
- jQuery, Bootstrap
- Analytics
- Google Tag Manager
- Cookie consent
- OneTrust
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.
Frequently asked
How much funding has Avidity Biosciences raised?
Avidity Biosciences has raised a total of $495M in funding. The most recent round on record is IPO.
How many employees does Avidity Biosciences have?
Avidity Biosciences has approximately 445 people on record.